Literature DB >> 17446061

Versican expression in human cervical cancer.

J Kodama1, T Kusumoto, N Seki, T Matsuo, K Nakamura, A Hongo, Y Hiramatsu.   

Abstract

Versican expression may enhance tumour invasion and metastasis. However, the expressions of versican in cervical cancer have seldom been characterised. The aim of this study was to investigate versican expression in human cervical cancers. We immunohistochemically investigated the expression of versican protein in 174 cervical cancers and analysed the correlation with various clinicopathological features, including patient outcome. Stromal versican expression was significantly higher in patients with lymph node metastasis (p<0.0001). Epithelial versican expression was significantly higher in patients with non-squamous cell cercinoma (p=0.0003), lymph-vascular space invasion (p=0.046), lymph node metastasis (p=0.009) and ovarian metastasis (p=0.0001). Multivariate analysis showed that high epithelial versican expression was an independent prognostic factor for disease-free survival. Versican enrichment of the tumour tissue may be associated with progression in cervical cancer. Versican expression can serve as an indicator of poor prognosis in patients with cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17446061     DOI: 10.1016/j.ejca.2007.02.007

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  14 in total

1.  Altered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometry.

Authors:  Yuan Tian; Francisco J Esteva; Jin Song; Hui Zhang
Journal:  Mol Cell Proteomics       Date:  2012-02-07       Impact factor: 5.911

Review 2.  Proteoglycans in liver cancer.

Authors:  Kornélia Baghy; Péter Tátrai; Eszter Regős; Ilona Kovalszky
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides.

Authors:  Hao Yang; Shan Liu; Huawei Cai; Lin Wan; Shengfu Li; Youping Li; Jingqiu Cheng; Xiaofeng Lu
Journal:  J Biol Chem       Date:  2010-05-18       Impact factor: 5.157

Review 4.  Antithetic roles of proteoglycans in cancer.

Authors:  Elena Garusi; Silvia Rossi; Roberto Perris
Journal:  Cell Mol Life Sci       Date:  2011-10-02       Impact factor: 9.261

5.  Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides.

Authors:  Miranda P Ween; Katja Hummitzsch; Raymond J Rodgers; Martin K Oehler; Carmela Ricciardelli
Journal:  Clin Exp Metastasis       Date:  2010-12-12       Impact factor: 5.150

6.  The role of shear stress and altered tissue properties on endothelial to mesenchymal transformation and tumor-endothelial cell interaction.

Authors:  Sara G Mina; Peter Huang; Bruce T Murray; Gretchen J Mahler
Journal:  Biomicrofluidics       Date:  2017-07-17       Impact factor: 2.800

7.  A role for versican in the development of leiomyosarcoma.

Authors:  Paul A Keire; Steven L Bressler; Joan M Lemire; Badreddin Edris; Brian P Rubin; Maziar Rahmani; Bruce M McManus; Matt van de Rijn; Thomas N Wight
Journal:  J Biol Chem       Date:  2014-10-15       Impact factor: 5.157

8.  Mechanisms of Hypoxic Up-Regulation of Versican Gene Expression in Macrophages.

Authors:  Fattah Sotoodehnejadnematalahi; Karl J Staples; Elvina Chrysanthou; Helen Pearson; Loems Ziegler-Heitbrock; Bernard Burke
Journal:  PLoS One       Date:  2015-06-09       Impact factor: 3.240

9.  Lumican and versican are associated with good outcome in stage II and III colon cancer.

Authors:  Meike de Wit; Eric J Th Belt; Pien M Delis-van Diemen; Beatriz Carvalho; Veerle M H Coupé; Hein B A C Stockmann; Herman Bril; Jeroen A M Beliën; Remond J A Fijneman; Gerrit A Meijer
Journal:  Ann Surg Oncol       Date:  2012-06-19       Impact factor: 5.344

10.  Therapeutic targeting of hyaluronan in the tumor stroma.

Authors:  Anne Kultti; Xiaoming Li; Ping Jiang; Curtis B Thompson; Gregory I Frost; H Michael Shepard
Journal:  Cancers (Basel)       Date:  2012-09-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.